echinomycin and Uterine-Cervical-Neoplasms

echinomycin has been researched along with Uterine-Cervical-Neoplasms* in 4 studies

Trials

3 trial(s) available for echinomycin and Uterine-Cervical-Neoplasms

ArticleYear
Echinomycin (NSC 526417) in recurrent and metastatic nonsquamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.
    American journal of clinical oncology, 1992, Volume: 15, Issue:4

    Eighteen evaluable patients with recurrent or metastatic nonsquamous carcinoma of the uterine cervix were treated with 1,500 micrograms/m2 of echinomycin every 4 weeks. Seven patients had received prior chemotherapy. There was one complete response (5.6%), 95% confidence interval for response of 0-27%. The major toxicity was nausea and vomiting, which was moderate to severe in eight patients. Myelosuppression was minimal. Echinomycin in this dose and schedule displays minimal activity in patients with advanced nonsquamous carcinoma of the cervix.

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Evaluation; Echinomycin; Female; Humans; Middle Aged; Uterine Cervical Neoplasms

1992
Echinomycin (NSC 526417) in recurrent and metastatic squamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group (GOG).
    Investigational new drugs, 1992, Volume: 10, Issue:1

    Nineteen evaluable patients with recurrent or metastatic squamous cell carcinoma of the uterine cervix were treated with 1,500 micrograms/m2 of echinomycin every 4 weeks. No patient had received prior chemotherapy. There was one partial response (5% response, 95% confidence interval for response of 0% to 26%). The major toxicity was nausea and vomiting which was moderate to severe in six patients. Myelosuppression was not observed. Echinomycin, in this dose and schedule displays no major activity in chemotherapy-naive patients with advanced squamous-cell carcinoma of the cervix.

    Topics: Carcinoma, Squamous Cell; Drug Evaluation; Echinomycin; Female; Humans; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms

1992
A phase II trial of echinomycin in metastatic cervix carcinoma.
    Investigational new drugs, 1990, Volume: 8, Issue:3

    Topics: Drug Evaluation; Echinomycin; Female; Humans; Uterine Cervical Neoplasms

1990

Other Studies

1 other study(ies) available for echinomycin and Uterine-Cervical-Neoplasms

ArticleYear
Echinomycin (NSC 526417) in squamous-cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.
    American journal of clinical oncology, 1990, Volume: 13, Issue:3

    Twenty-eight evaluable patients with advanced or recurrent squamous-cell carcinoma of the cervix were treated with 1,500 micrograms/m2 of echinomycin every 4 weeks. All patients had prior chemotherapy. Two patients had partial responses (7% response, 95% confidence interval for response of 1 to 24%). The major toxicity was nausea and vomiting. Myelosuppression and other toxicity were modest. Echinomycin, at this dose and schedule, displays minimal activity in patients with squamous-cell carcinoma of the cervix who have had prior chemotherapy.

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Echinomycin; Female; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinoxalines; Uterine Cervical Neoplasms

1990